Oramed Pharmaceuticals Terminates Material Agreement
Ticker: ORMP · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.012, $75,000,000, $100,000,000, $26.25 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, financial-statements
TL;DR
Oramed just terminated a big deal, filing shows.
AI Summary
Oramed Pharmaceuticals Inc. announced on March 18, 2024, the termination of a material definitive agreement. The company also reported on financial statements and exhibits, indicating potential shifts in its financial or operational landscape.
Why It Matters
The termination of a material definitive agreement could signal a change in Oramed's strategic partnerships or operational plans, potentially impacting its drug development pipeline.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can introduce uncertainty regarding future operations and financial stability.
Key Players & Entities
- ORAMED PHARMACEUTICALS INC. (company) — Registrant
- March 18, 2024 (date) — Date of earliest event reported
FAQ
What was the specific material definitive agreement that was terminated?
The filing does not specify the exact name or details of the material definitive agreement that was terminated.
What are the implications of this termination for Oramed's ongoing projects?
The filing does not provide details on the specific implications of the termination for Oramed's ongoing projects.
When was the agreement entered into?
The filing does not state the date when the terminated agreement was originally entered into.
Are there any financial penalties associated with this termination?
The filing does not disclose any information regarding financial penalties related to the termination.
What specific financial statements and exhibits are being reported?
The filing mentions 'Financial Statements and Exhibits' as an item of disclosure but does not list the specific documents included.
Filing Stats: 1,181 words · 5 min read · ~4 pages · Grade level 11.9 · Accepted 2024-03-18 17:05:37
Key Financial Figures
- $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, Tel
- $75,000,000 — ximum aggregate offering price of up to $75,000,000 from time to time through the Agents.
- $100,000,000 — ng an aggregate offering price of up to $100,000,000 from time to time through Cantor Fitzge
- $26.25 million — ion, the Company received approximately $26.25 million in net proceeds from the sales of its c
Filing Documents
- ea0201743-8k_oramed.htm (8-K) — 43KB
- ea020174301ex1-1_oramed.htm (EX-1.1) — 308KB
- ea020174301ex5-1_oramed.htm (EX-5.1) — 13KB
- image_001.jpg (GRAPHIC) — 17KB
- image_002.jpg (GRAPHIC) — 6KB
- 0001213900-24-023571.txt ( ) — 633KB
- ormp-20240318.xsd (EX-101.SCH) — 3KB
- ormp-20240318_lab.xml (EX-101.LAB) — 33KB
- ormp-20240318_pre.xml (EX-101.PRE) — 22KB
- ea0201743-8k_oramed_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO March 18, 2024 3